|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Springworks Therapeutics, Inc. (SWTX) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
79,266,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile SpringWorks Therapeutics a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing medicines for underserved patient populations suffering from devastating rare diseases and cancer. Co.'s product candidate, nirogacestat, is an oral, small molecule gamma secretase inhibitor in development as a monotherapy for the treatment of desmoid tumors, a rare and often debilitating and disfiguring soft tissue tumor. Co.'s second product candidate is mirdametinib, an oral, small molecule MEK inhibitor initially in development for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
15,000 |
49,237 |
54,055 |
2,234,484 |
| Total Sell Value |
$751,550 |
$2,293,323 |
$2,428,802 |
$67,748,752 |
| Total People Sold |
1 |
2 |
3 |
5 |
| Total Sell Transactions |
1 |
4 |
6 |
12 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ashar Bhavesh |
Chief Commercial Officer |
• – – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
26,445 |
70,166 |
|
- |
|
| Edris Badreddin |
Chief Operating Officer |
• – – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
42,312 |
279,535 |
|
- |
|
| Islam Saqib |
Chief Executive Officer |
• • – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
88,000 |
287,053 |
|
- |
|
| Nofi Michael |
Chief Accounting Officer |
• – – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
14,104 |
30,959 |
|
- |
|
| Cassidy James |
Chief Medical Officer |
• – – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
28,208 |
79,866 |
|
- |
|
| Smith L. Mary |
Chief Development Officer |
• – – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
21,156 |
239,095 |
|
- |
|
| Francis Perier I Jr |
Chief Financial Officer |
• – – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
21,156 |
64,619 |
|
- |
|
| Lin Tai-An |
Chief Scientific Officer |
• – – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
5,289 |
29,289 |
|
- |
|
| Pichl Daniel |
Chief People Officer |
• – – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
22,919 |
58,122 |
|
- |
|
| Weinstein Herschel S |
General Counsel & Secretary |
• – – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
21,156 |
56,986 |
|
- |
|
| Islam Saqib |
Chief Executive Officer |
• • – |
2023-11-30 |
4 |
A |
$0.00 |
$0 |
D/D |
199,053 |
199,053 |
|
- |
|
| Lin Tai-An |
Chief Scientific Officer |
• – – |
2023-10-02 |
4 |
A |
$0.00 |
$0 |
D/D |
24,000 |
24,000 |
|
- |
|
| Cassidy James |
Chief Medical Officer |
• – – |
2023-09-01 |
4 |
D |
$30.33 |
$39,186 |
D/D |
(1,292) |
51,658 |
|
- |
|
| Hambleton Julie |
Director |
– • – |
2023-07-19 |
4 |
AS |
$29.31 |
$70,876 |
D/D |
(2,418) |
4,648 |
|
- |
|
| Smith L. Mary |
Chief Development Officer |
• – – |
2023-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
5,720 |
217,939 |
|
- |
|
| Cassidy James |
Chief Medical Officer |
• – – |
2023-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
5,720 |
52,950 |
|
- |
|
| Hambleton Julie |
Director |
– • – |
2023-06-20 |
4 |
AS |
$26.92 |
$64,603 |
D/D |
(2,400) |
7,066 |
|
- |
|
| Hambleton Julie |
Director |
– • – |
2023-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,648 |
9,466 |
|
- |
|
| Lewis-Hall Freda C |
Director |
– • – |
2023-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,648 |
10,572 |
|
- |
|
| Fuhrman Alan |
Director |
– • – |
2023-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,648 |
10,572 |
|
- |
|
| Lynch Daniel |
Director |
– • – |
2023-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,648 |
301,849 |
|
- |
|
| Alban Carlos |
Director |
– • – |
2023-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,648 |
14,706 |
|
- |
|
| Schwartz Jeffrey Lawrence |
Director |
– • – |
2023-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,648 |
10,572 |
|
- |
|
| Ashar Bhavesh |
Chief Commercial Officer |
• – – |
2023-04-03 |
4 |
D |
$25.25 |
$34,719 |
D/D |
(1,375) |
43,721 |
|
- |
|
| Schwartz Jeffrey Lawrence |
Director |
– • – |
2023-03-16 |
4 |
S |
$28.50 |
$49,875,000 |
I/I |
(1,750,000) |
3,081,307 |
|
- |
|
184 Records found
|
|
Page 2 of 8 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
